New Gadolinium-Free MRI dye shows promise for brain scans

NCT ID NCT06322342

Completed Diagnosis Sponsor: Reveal Pharmaceuticals Inc. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a new MRI contrast agent called RVP-001, made with manganese instead of gadolinium, in 18 adults with known brain lesions (like tumors or multiple sclerosis). The goal was to see if it is safe and can detect lesions as well as current gadolinium-based dyes. Each participant received one dose of RVP-001 and had their scans compared to earlier gadolinium-enhanced MRIs.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: RVP-001 (manganese-based MRI contrast agent)
What this could lead to: If successful, this could provide a safer, gadolinium-free alternative for MRI scans to detect brain lesions and tumors.
What could go wrong: This is a small, early-phase trial with only 18 participants, so results may not apply to everyone. The new agent may not work as well as current gadolinium-based contrasts.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACOUSTIC NEUROMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acoustic neuroma benign neoplasm of brain brain cancer brain neoplasm central nervous system cancer central nervous system neoplasm glioblastoma glioma meningioma metastatic malignant neoplasm in the brain multiple sclerosis neoplasm Neurilemmoma neurofibroma Neuroinflammatory Diseases neuronitis primary brain neoplasm primary central nervous system lymphoma schwannoma von Hippel-Lindau disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACOUSTIC NEUROMA BRAIN CANCER BRAIN METASTASES BRAIN NEOPLASM, PRIMARY BRAIN NEOPLASMS BRAIN NEOPLASMS, BENIGN BRAIN TUMOR BRAIN TUMOR RECURRENT BRAIN TUMOR, PRIMARY BRAIN TUMORS CENTRAL NERVOUS SYSTEM (CNS) LESIONS CNS CANCER CNS LESION CNS LYMPHOMA CNS METASTASES CNS TUMOR GLIOMA MENINGIOMA MULTIPLE SCLEROSIS MULTIPLE SCLEROSIS BRAIN LESION NEOPLASIA NEUROFIBROMA NEUROINFLAMMATION SCHWANNOMAS VON HIPPEL LINDAU

Contacts and locations

Locations

Brigham & Women's Hospital

Boston, Massachusetts, 02115, United States
Duke University Medical Center

Durham, North Carolina, 27710, United States
Massachusetts General Hospital

Boston, Massachusetts, 02114, United States
University of Missouri

Columbia, Missouri, 65212, United States
Yale New Haven Hospital

New Haven, Connecticut, 06510, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.